Carcinogenicity studies in drug preclinical safety studies have important effects on clinical trials and marketing authorization for medicines.In some developed countries,the short/medium term models have been used as an additional component of the potential carcinogenicity assessment, in place of 2-year mouse bioassay.Based on the data and information obtained from chemical carcinogenicity evaluation,we overview the characteristics and recent application of these models here.Then faced with the shortages of these models,the demand for developing new pharmaceutical at home and the international circulation of pharmaceutical,we suppose that the creation of new humanized model which has defects in functions of DNA damage repair and cell cycle check-point appears to be a very promising alternative model.